New hope for men with mCRPC

Androgen deprivation therapy has been the mainstay of treatment for advanced and metastatic prostate cancer, but the treatment is not curative and most men progress to mCRPC.

Read More
CPD POINTS: 0

Hodgkin lymphoma guideline 2018

Specialist Forum December 2018 CPD 3 of 3: With modern treatment strategies, 80%–90% of patients with Hodgkin lymphoma achieve permanent remission, according to the European Society for Medical Oncology’s new HL guideline.

Read More
CPD POINTS: 0

Management of post-radical prostatectomy ED

MEDICAL CHRONICLE NOVEMBER 2 of 3: Radical prostatectomy is a commonly performed procedure for the treatment of localised prostate cancer. One of the long-term complications is erectile dysfunction (ED).

Read More
CPD POINTS: 0

Prostate cancer: Salvage options for failure post-primary radiotherapy

Radiotherapy for localised prostate cancer is a standard option, but unfortunately a significant number of patients will experience prostate-specific antigen failure after treatment.

Read More
CPD POINTS: 0

Breast cancer: the importance of early diagnosis and treatment

MEDICAL CHRONICLE OCTOBER CPD 2 of 4: Breast cancer is the most common of all cancers in women, with the lifetime risk of getting breast cancer in South African women being 1 out of every 26.

Read More
CPD POINTS: 0

Changing the oncology landscape

Immunotherapy has dramatically changed the oncology landscape and improved patient outcomes, but dealing with immune-related adverse events (irAEs) can be challenging.

Read More
CPD POINTS: 0

Cervical cancer: HPV and screening

MEDICAL CHRONICLE JULY 2018: CPD 5 of 5

Read More
CPD POINTS: 0

Building a palliative care curriculum for oncologists

Palliative care improves patients facing life threatening illness quality of life through the prevention and the relief of suffering by means of biopsychosocial and spiritual care.

Read More
CPD POINTS: 3

A practical approach to oral and dermatological toxicities caused by anticancer therapies

Advances in the treatment of potentially life-threatening diseases such as cancer, are often accompanied by side effects, which can severely affect patients’ quality of life (QOL). As a result, some patients discontinue treatment.

Read More
CPD POINTS: 3

MSD announces local regulatory approval of new oncology drug

In recognising the impact that Pembrolizumab would have in oncology treatment, MSD received regulatory approval by the Medicines Control Council (now South African Health Products Regulatory Authority) in South Africa.

Read More
CPD POINTS: 0

Rare but there

Male breast cancer is an uncommon disease that has been the focus of limited research. Because this disease is rare, no randomised trials have been possible.

Read More
CPD POINTS: 3